Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
{{output}}
Background Despite definitive local therapy, patients with high-risk prostate cancer have a significant risk for local and distant failure. To date, no systemic therapy given prior to surgery has been shown to improve outcomes. The phosphatidilinositol 3-kinas... ...
